Hurley Capital, LLC Biogen Inc. Transaction History

Hurley Capital, LLC

$178 Billion
Q3 2025

A detailed history of Hurley Capital, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Hurley Capital, LLC holds 2 shares of BIIB stock, worth $335. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$335

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2025 Nov 10, 2025	BUY	$122.68 - $148.84 $245 - $297	2 New	2 $280,000
Q1 2025 May 07, 2025	BUY	$133.43 - $153.27 $1,334 - $1,532	10 New	10 $1.37 Million

Others Institutions Holding BIIB

# of Institutions

1,074

Shares Held

131M

Call Options Held

3.77M

Put Options Held

2.31M

Vanguard Group Inc Valley Forge, PA

17.3M
Shares

$2.9 Billion
0.04% of portfolio
Primecap Management CO Pasadena, CA

15M
Shares

$2.51 Billion
1.66% of portfolio
Black Rock Inc. New York, NY

14.5M
Shares

$2.44 Billion
0.08% of portfolio
State Street Corp Boston, MA

7.32M
Shares

$1.23 Billion
0.04% of portfolio
Wellington Management Group LLP Boston, MA

4.25M
Shares

$712 Million
0.11% of portfolio

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $24.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hurley Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hurley Capital, LLC with notifications on news.

Account